Comparison

Recombinant Mouse Noggin

Item no. CS-CSI20130B
Manufacturer Cell Sciences
Amount 20 ug
Category
Type Proteins
Specific against Mouse (Murine, Mus musculus)
Host E.coli
Purity >95% by SDS-PAGE and HPLC
Sequence MQHYLHIRPA PSDNLPLVDL IEHPDPIFDP KEKDLNETLL RSLLGGHYDP GFMATSPPED RPGGGGGPAG GAEDLAELDQ LLRQRPSGAM PSEIKGLEFS EGLAQGKKQR LSKKLRRKLQ MWLWSQTFCP VLYAWNDLGS RFWPRYVKVG SCFSKRSCSV PEGMVCKPSK SVHLTVLRWR CQRRGGQRCG WIPIQYPIIS ECKCSC
ECLASS 10.1 32160409
ECLASS 11.0 32160409
UNSPSC 12352202
Available
Biological Activity
Fully biologically active when compared to standard. The ED50 determined by inhibiting BMP-4-induced alkaline phosphatase production ofmouse ATDC5 cells is less than 2 ng/ml.
Description
Noggin belongs to a group of diffusible proteins which bind to ligands of the TGF-beta family and regulate their activity by inhibiting their access to signaling receptors. The interplay between TGF-beta ligands and their natural antagonists has major biological significance during development processes, in which cellular response can vary considerably depending upon the local concentration of the signaling molecule. Noggin was originally identified as a BMP-4 antagonist whose action is critical for proper formation of the head and other dorsal structures. Consequently, Noggin has been shown to modulate the activities of other BMPs including BMP-2, -7, -13, and -14. Targeted deletion of Noggin in mice results in prenatal death and recessive phenotype displaying a severely malformed skeletal system. Conversely, transgenic mice over-expressing Noggin in mature osteoblasts display impaired osteoblastic differentiation, reduced bone formation, and severe osteoporosis.
Endotoxin Level
Less than 1EU/ug of rMuNoggin as determined by LAL method.
Formulation
Lyophilized from a 0.2um filtered concentrated solution in 30% acetonitrile, 0.1% TFA.
Molecular Weight
Approximately 46.4 kDa disulfide-linked homodimer consisting of two 206 amino acid polypeptide chains.
Reconstitution
Centrifuge vial prior to opening. Reconstitute in 10 mM HAc to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at <-20C. Further dilutions should be made in appropriate buffered solutions. Please note that the addition of any carrier protein into this product may produce unwanted endotoxin. This depends upon the particular application employed.
Storage and Stability
This lyophilized preparation is stable at 2-4C, but should be kept desiccated at -20C for long term storage. Upon reconstitution, the preparation is stable for up to one week at 2-4C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20C to -80C. Avoid repeated freeze/thaw cycles.
Specificity
„ 5.0 ca. 105 IU/mg in the presence of 5 ng/ml BMP-4.

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 20 ug
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close